Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
Phase 1UNKNOWN 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal Cancer
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma, Prostate Cancer, Gastric Cancer
Trial Timeline
Dec 1, 2019 โ Mar 1, 2021
NCT ID
NCT04107142About Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell is a phase 1 stage product being developed by CytoMed Therapeutics for Colorectal Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04107142. Target conditions include Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04107142 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Colorectal Cancer